Abstract Details
| Presented By: | Brooks, Amanda |
| Affiliated with: | University of Utah, Pharmaceutics and Pharmaceutical CHemistry |
| Authors: | Amanda E. Brooks, Paul C. Hogrebe, David W. Grainger |
| From: | University of Utah |
Title
Abstract
Bone autograft material (patient-derived human-harvested bone) is the gold standard for ~500,000 U.S. bone grafting procedures annually, providing biomaterials integration into various wound sites. However, limited patient harvesting availability makes cadaveric allograft bone material (donor-derived processed bone) an increasingly popular clinical, commercial, FDA-approved alternative. Non-cadaveric bone is preferable, yet reliable synthetic bone graft products are only recently available. Despite improvements in surgical techniques and treatments, costly bone infections frequently arise, sourced to surgical sites by intra-operative opportunistic pathogen introduction. Opportunities to endow the graft implant materials with antimicrobial properties will help eliminate infection locally at surgical wound sites. Direct antibiotic delivery from bone filler materials packed into defect sites is such a strategy. We have developed antimicrobial allograft bone fragments and micron-sized bone particulate matter to fill infectious, traumatic, or surgically induced bone defects. Antibiotic release from the graft biomaterial is controlled using a customizable antibiotic-loaded coating of FDA-approved, biodegradable polycaprolactone (PCL) polymer coated over each granule. A versatile new anti-infective surgical orthopeadic bone graft biomaterial for trauma, revision surgeries and major repairs is directed to a substantial targeted market niche.